REPL Healthcare

Replimune Group, Inc.

$20.65+5.95%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 1.9B USD
Enterprise value: 912.0M USD
Full-time employees: 465

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 0.94 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.94 vs peers 0.63)
Drawback: more debt relative to equity (0.80× vs a peer median of 0.22×)more debt vs equity (0.80× vs peers 0.22×)
About average: risk (debt, liquidity and share-price swings)risk
Not enough data: growth

Would rank #1,119 of 1,157 fully scored healthcare companies (bottom 4%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 66% from March 2023 to August 2026.
Replimune had 66% more shares at August 2026 than at March 2023, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Replimune had 66% more shares at August 2026 than at March 2023, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Replimune looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Replimune reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

18/ 100

Oct 5 18 → Nov 4 18

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 12.2% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-15.3%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-16.3%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-14.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield5.4%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

8/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-117.6%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-5345.9%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-281.1%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Current ratio
▼ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.94

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.94Sector median: 0.6250 · MAD: 0.3380

Current ratio5.23×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.91Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.80×

SEC filings · latest balance sheetReported value33% base weight · Z-score -2.82Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Replimune

Is Replimune getting weaker?: Its latest SEC filing (Aug 14, 2026) got weaker in some ways: share count up 12.2%. Its overall score is unchanged at 18/100 since Oct 28, 2026.
How is Replimune valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -15.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -15.3% vs peers 1.5% (weaker than 100% of peers).
Is Replimune growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Replimune?: Less profitable than most of its peers. Profitability scores 8/100 against 1,393 healthcare peers. Return on assets -117.6% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -117.6% vs peers 1.7% (weaker than 100% of peers).
How risky is Replimune?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 5.23× vs a peer median of 2.59× (stronger than 75% of peers).Current ratio 5.23× vs peers 2.59× (stronger than 75% of peers). Debt / equity 0.80× vs a peer median of 0.22× (weaker than 77% of peers).Debt / equity 0.80× vs peers 0.22× (weaker than 77% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 14, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Share count up 12.2% (existing holders diluted)

Worth watching: Replimune is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Net income (12 months)	−313.9M USD	−297.0M USD	−5.4%
Free cash flow (12 months)	−284.6M USD	−280.5M USD	−1.4%
Debt	83.3M USD	84.1M USD	+1.0%
Cash	209.0M USD	185.4M USD	−11.3%
Shares outstanding	83.9M	94.2M	+12.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Mar 2022	FY Mar 2023	FY Mar 2024	FY Mar 2025	FY Mar 2026	Change
Return on assets (ROA)	-25.6%	-27.0%	-44.2%	-44.9%	-94.4%	▼ 50 pts
Return on equity (ROE)	-28.7%	-31.4%	-57.6%	-59.5%	-188.9%	▼ 129 pts
Current ratio	19.46×	17.52×	10.72×	7.95×	4.79×	▼ 40%
Debt to equity	0.00×	0.05×	0.12×	0.11×	0.50×	▲ 350%
Interest coverage	—	-90.21×	-52.21×	-45.30×	-47.07×	▼ 3.9%

REPL price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 0.94 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.94 vs peers 0.63)

Drawback: more debt relative to equity (0.80× vs a peer median of 0.22×)more debt vs equity (0.80× vs peers 0.22×)

About average: risk (debt, liquidity and share-price swings)risk

Not enough data: growth

Would rank #1,119 of 1,157 fully scored healthcare companies (bottom 4%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 66% from March 2023 to August 2026.

Replimune had 66% more shares at August 2026 than at March 2023, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Replimune had 66% more shares at August 2026 than at March 2023, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Replimune looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Replimune reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Replimune

Is Replimune getting weaker?

Its latest SEC filing (Aug 14, 2026) got weaker in some ways: share count up 12.2%. Its overall score is unchanged at 18/100 since Oct 28, 2026.

How is Replimune valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -15.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -15.3% vs peers 1.5% (weaker than 100% of peers).

Is Replimune growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Replimune?

Less profitable than most of its peers. Profitability scores 8/100 against 1,393 healthcare peers. Return on assets -117.6% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -117.6% vs peers 1.7% (weaker than 100% of peers).

How risky is Replimune?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 5.23× vs a peer median of 2.59× (stronger than 75% of peers).Current ratio 5.23× vs peers 2.59× (stronger than 75% of peers). Debt / equity 0.80× vs a peer median of 0.22× (weaker than 77% of peers).Debt / equity 0.80× vs peers 0.22× (weaker than 77% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−313.9M USD

−297.0M USD

−5.4%

Free cash flow (12 months)

−284.6M USD

−280.5M USD

−1.4%

Debt

83.3M USD

84.1M USD

+1.0%

Cash

209.0M USD

185.4M USD

−11.3%

Shares outstanding

83.9M

94.2M

+12.2%

Key ratios

FY Mar 2022

FY Mar 2023

FY Mar 2024

FY Mar 2025

FY Mar 2026

Change

Return on assets (ROA)

-25.6%

-27.0%

-44.2%

-44.9%

-94.4%

▼ 50 pts

Return on equity (ROE)

-28.7%

-31.4%

-57.6%

-59.5%

-188.9%

▼ 129 pts

Current ratio

19.46×

17.52×

10.72×

7.95×

4.79×

▼ 40%

Debt to equity

0.00×

0.05×

0.12×

0.11×

0.50×

▲ 350%

Interest coverage

—

-90.21×

-52.21×

-45.30×

-47.07×

▼ 3.9%